PEG-PPS and PEG-SS-PPS nanomaterials have already shownbiocompatibility and translational promise in therapeutics, diagnostics,and immune modulation,36,38−41,59,60 and this work adds the ability to targetPSOMs using the specificity and affinity of F(ab) antibody fragments.A parallel body of research uses CD19-targeted liposomes to deliverchemotherapeutics to DLBCL.46,61−65 The CD19-targeted PSOMs presented here aim to expand on this tenet,utilizing the benefits of improved stability, PEGylation, and syntheticflexibility of PSOMs compared to liposomes.66−68. Here, CD19 is linked to diffuse large B-cell lymphoma.